SCTX · Scribe Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Aghazadeh Behzad Director | ▲ Buy | Open Market | 3,088,888 Shares held | 7/28/2026 | View profile |
| AH Bio Fund II, L.P. | ▲ Buy | Open Market | 2,385,075 Shares held | 7/27/2026 | View profile |
| ORBIMED ADVISORS LLC Director | ▲ Buy | Open Market | 1,348,825 Shares held | 7/27/2026 | View profile |
| Carl L. Gordon Director | ▲ Buy | Open Market | 1,348,825 Shares held | 7/27/2026 | View profile |
| Jennifer A. Doudna | ▼ Sell | Other | 603,547 Shares held | 7/27/2026 | View profile |
| Svetlana Lucas Director | ▲ Buy | Open Market | 3,000 Shares held | 7/23/2026 | View profile |
| Parrot David Chief Financial Officer | ▲ Buy | Open Market | 1,333 Shares held | 7/23/2026 | View profile |
Transaction History
| Aghazadeh Behzad | ▲ Buy | Open Market | 7,905 | $144K | 7/28/2026 |
| ORBIMED ADVISORS LLC | ▲ Buy | Open Market | 1,000,000 | $15.0M | 7/27/2026 |
| AH Bio Fund II, L.P. | ▲ Buy | Open Market | 333,333 | $5.0M | 7/27/2026 |
| Carl L. Gordon | ▲ Buy | Open Market | 1,000,000 | $15.0M | 7/27/2026 |
| Carl L. Gordon | ▼ Sell | Other | 348,825 | — | 7/27/2026 |
| Jennifer A. Doudna | ▼ Sell | Other | 12,511 | — | 7/27/2026 |
| ORBIMED ADVISORS LLC | ▼ Sell | Other | 348,825 | — | 7/27/2026 |
| AH Bio Fund II, L.P. | ▼ Sell | Other | 2,051,742 | — | 7/27/2026 |
| AH Bio Fund II, L.P. | ▼ Sell | Other | 697,650 | — | 7/27/2026 |
| Aghazadeh Behzad | ▲ Buy | Open Market | 2,333,333 | $35.0M | 7/24/2026 |
| Aghazadeh Behzad | ▲ Buy | Open Market | 50,000 | $1.1M | 7/24/2026 |
| Parrot David | ▲ Buy | Open Market | 1,333 | $20K | 7/23/2026 |
| Parrot David | ▲ Buy | Open Market | 1,333 | $20K | 7/23/2026 |
| Svetlana Lucas | ▲ Buy | Open Market | 3,000 | $45K | 7/23/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings
ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.
Cathie Wood's ARKG adds Scribe Therapeutics to its biotech holdings. ARK Genomic Revolution ETF (ARKG) increased its position in Scribe Therapeutics, as reported by Yahoo and Benzinga. The addition places Scribe among four biotech names that the fund has recently loaded up on. The stock also appeared in a list of health‑care shares moving in the pre‑market session. This news brings additional attention to the company while the stock shows modest momentum on the chart.